Our Pricing

Order Weight Loss Injections Online Today

When you order weight loss injections online UK through Cured Pharmacy, you access genuine MHRA-licensed treatments with transparent pricing, free clinical consultations completed in under three minutes, and discreet next-day delivery. Our UK-registered prescribers assess every patient individually, ensuring you receive the safest, most effective treatment for your weight management goals.

How Weight Loss Injections Work in the UK

Weight loss injections available in the UK belong to a class of medications called GLP-1 receptor agonists, which mimic natural hormones that regulate appetite and blood sugar control [1]. These medications work by slowing gastric emptying, reducing hunger signals to the brain, and improving insulin sensitivity—mechanisms that together create significant caloric reduction without the need for extreme dietary restriction.

Tirzepatide (Mounjaro) represents the latest advancement, acting as a dual GIP/GLP-1 receptor agonist. In the SURPASS-2 trial, patients achieved an average weight reduction of 22.5% over 72 weeks on the 15mg dose, compared to 15.8% with semaglutide 1mg [1]. Semaglutide injections (Wegovy) and liraglutide (Saxenda) remain highly effective alternatives, with the STEP-1 trial demonstrating average weight loss of 14.9% over 68 weeks with semaglutide [2].

All prescription weight loss injections require clinical assessment by a UK-registered prescriber before dispensing. At Cured Pharmacy, our clinical team evaluates your medical history, current medications, and weight management goals to determine the most appropriate treatment and starting dose for your individual circumstances.

Comparing Mounjaro, Wegovy and Saxenda

Mounjaro (tirzepatide) offers the highest average weight reduction in clinical trials, making it particularly suitable for patients with significant weight to lose or those who haven't achieved goals with other treatments [1]. The once-weekly injection starts at a lower dose and gradually increases, minimising gastrointestinal side effects during the titration period.

Wegovy (semaglutide) provides robust weight loss outcomes at a lower starting price point. Clinical data shows 86.4% of patients achieved at least 5% weight loss, with 69.1% reaching 10% or more in the STEP-1 trial [2]. The dosing schedule follows a similar gradual escalation over 16-20 weeks to the maintenance dose of 2.4mg weekly.

Saxenda (liraglutide) requires daily injections rather than weekly administration, which some patients prefer for more consistent appetite control throughout the week. While average weight loss is lower than the newer agents—approximately 8% in the SCALE trial—it remains an effective option, particularly for patients who don't tolerate higher-potency GLP-1 treatments [3].

Which Injection Is Right for You?

Your UK prescriber will consider multiple factors when recommending a specific weight loss injection: your BMI, previous weight loss attempts, medical conditions such as type 2 diabetes or cardiovascular disease, current medications, and budget considerations. Patients with diabetes may benefit particularly from tirzepatide's superior glycaemic control, while those prioritising cost-effectiveness might start with semaglutide or liraglutide.

All three medications require commitment to lifestyle modifications including balanced nutrition and regular physical activity. Clinical trials demonstrating significant weight loss included dietary counselling and exercise recommendations as standard components of treatment [1][2][3]. Your prescriber will provide specific guidance on optimising results through sustainable behavioural changes.

Order Weight Loss Injections Online: The Clinical Process

When you order weight loss injections online through Cured Pharmacy, you complete a comprehensive medical questionnaire reviewed by our UK-registered prescribers. This assessment covers your weight history, previous weight loss attempts, current medications, cardiovascular health, thyroid function, and any contraindications to GLP-1 therapy.

Our clinical team operates under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073), ensuring every prescription meets General Pharmaceutical Council standards for remote consultations. If your prescriber identifies any concerns—such as a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2—they will recommend alternative treatments or suggest an in-person GP review before proceeding [4].

Once approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and dispatched in discreet packaging with next-day delivery options. Each package includes detailed injection technique instructions, sharps disposal guidance, and information on managing potential side effects. Our pharmacy team remains available by phone on (+44) 116 4646009 for any questions during your treatment.

Transparent Pricing Before Consultation

Unlike many online services, Cured Pharmacy displays exact pricing before you begin your consultation. Mounjaro starts from £135.00, with the specific cost determined by your prescribed dose strength. This upfront transparency allows you to make informed decisions about treatment affordability without hidden fees or surprise charges after clinical approval.

We guarantee the lowest prices in the UK for genuine, MHRA-licensed weight loss injections. If you find a lower price elsewhere for the same product and dose from a GPhC-registered pharmacy, we'll match it. Our pricing includes the clinical consultation, prescription, medication, and standard delivery—no additional charges apply.

Managing Side Effects and Treatment Expectations

Gastrointestinal side effects represent the most common adverse reactions with GLP-1 weight loss injections. In clinical trials, nausea affected 44% of tirzepatide patients (versus 17% on placebo), with most cases rated as mild to moderate and resolving within 4-8 weeks [1]. Diarrhoea, constipation, and abdominal discomfort occur less frequently but may require dietary adjustments or temporary dose reductions.

Starting at lower doses and following the prescribed titration schedule significantly reduces side effect severity. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated helps minimise gastrointestinal symptoms during the initial weeks. If side effects persist or worsen, contact your prescriber—they may recommend slowing the dose escalation or switching to an alternative treatment.

Realistic expectations matter for long-term success. While clinical trials show impressive average weight loss figures, individual results vary based on adherence, lifestyle factors, and metabolic differences [1][2][3]. Most patients begin noticing appetite reduction within the first week, with measurable weight loss typically evident by week 4-6. Optimal results require 6-12 months of consistent treatment combined with sustainable dietary and activity changes.

Clinical Evidence Supporting Weight Loss Injections

The SURMOUNT-1 trial evaluated tirzepatide specifically for weight management in non-diabetic adults, demonstrating average weight reductions of 15.0%, 19.5%, and 20.9% with 5mg, 10mg, and 15mg doses respectively over 72 weeks [5]. These results exceeded all previous weight loss medication trials and approached outcomes typically seen only with bariatric surgery.

Semaglutide's efficacy is established through the STEP trial programme, with STEP-1 showing 14.9% average weight loss and STEP-2 demonstrating particular benefit in patients with type 2 diabetes (9.6% weight reduction versus 3.4% with placebo) [2]. The SCALE trial programme for liraglutide showed 8.0% average weight loss over 56 weeks, with 63.2% of patients achieving at least 5% weight reduction [3].

Long-term data increasingly supports sustained weight loss maintenance with continued treatment. However, weight regain commonly occurs after discontinuation, with the STEP-1 extension study showing patients regained two-thirds of lost weight within one year of stopping semaglutide [6]. This highlights the importance of viewing these medications as long-term management tools rather than short-term fixes, similar to treatments for other chronic conditions like hypertension or diabetes.

Cardiovascular and Metabolic Benefits

Beyond weight reduction, GLP-1 receptor agonists provide significant cardiovascular and metabolic improvements. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease, independent of weight loss effects [7]. Blood pressure reductions averaging 6-7 mmHg systolic and improvements in lipid profiles occur consistently across trials [2][7].

For patients with prediabetes or metabolic syndrome, weight loss injections substantially reduce progression to type 2 diabetes. In the STEP programme, 84% of participants with prediabetes at baseline achieved normoglycaemia after 68 weeks of semaglutide treatment [2]. These broader health benefits often justify long-term treatment even in patients who achieve their initial weight goals.

Who Can Order Weight Loss Injections Online?

NICE guidelines recommend considering GLP-1 weight loss medications for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea [8]. UK prescribers follow these evidence-based thresholds when assessing eligibility during online consultations.

Certain medical conditions contraindicate GLP-1 therapy. Patients with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease should not use these medications [4]. Pregnancy and breastfeeding represent absolute contraindications—women of childbearing potential should use reliable contraception and discontinue treatment at least 2 months before attempting conception.

Age considerations apply as well. Clinical trials primarily enrolled adults aged 18-75, with limited safety data in older populations. Patients over 75 may still be prescribed weight loss injections if their prescriber determines benefits outweigh risks, though dose adjustments and more frequent monitoring may be necessary. Adolescents aged 12-17 may be considered for certain treatments under specialist guidance, though this falls outside standard online prescribing pathways.

Medication Interactions and Precautions

Weight loss injections slow gastric emptying, which can affect absorption of oral medications. Patients taking medications with narrow therapeutic windows—such as warfarin, levothyroxine, or certain antibiotics—may require dose adjustments or timing modifications [4]. Always disclose all current medications, including over-the-counter products and supplements, during your clinical assessment.

Patients with a history of pancreatitis should use GLP-1 treatments with caution, as these medications have been associated with acute pancreatitis in rare cases [4]. Persistent severe abdominal pain radiating to the back warrants immediate medical attention and treatment discontinuation. Similarly, symptoms of gallbladder disease—which occurs more frequently during rapid weight loss—require prompt evaluation.

Scientific References

1. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
4. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/14881/smpc
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
6. Wilding, J. P. H., et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
7. Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
8. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). Retrieved from https://www.nice.org.uk/guidance/cg189

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.